Prognos, a company that uses artificial intelligence (AI) for the benefit of the healthcare industry, has launched after six years of development under the name Medivo.
Supported by Merck Global Health Innovation Fund and Safeguard Scientifics, the company strives to improve health by tracking and predicting disease earlier in partnership with Life Sciences brands, payers, and clinical diagnostics organizations.
The Prognos Registry of 5 billion clinical records for 100 million patients in over 30 disease areas enables earlier identification of patients who can benefit from enhanced treatment decision-making, risk management, and quality improvement under the HEDIS guidelines. During its research and development phase as Medivo, Prognos invested in innovations exploring the potential of clinical diagnostic assets and is now realizing the full value of those assets through AI and HIPAA-compliant advanced analytics with over 500 proprietary and learning clinical algorithms.
"The launch of Prognos elevates our ability to leverage the largest aggregated database of lab results in the U.S. and deliver actionable clinical insights to the medical community," said Sundeep Bhan, Prognos co-founder and CEO.
Prognos, Medivo, Artificial intelligence, Healthcare, North America